{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086529","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.657557+00:00","generated_at":"2026-05-31T11:52:08.636438+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Liquidia Q2 net loss $27.9M; court rulings clear legal path for YUTREPIA approval","bullets":["Q2 net loss $27.9M ($0.37/share) vs $23.5M ($0.36/share) in Q2 2023.","Revenue from Sandoz promotion $3.7M, down from $4.8M due to lower sales volumes.","Cash and equivalents $133.1M at June 30, 2024, up from $83.7M at Dec 31, 2023.","Court denied UTHR's preliminary injunction on YUTREPIA patent '327 on May 31; D.C. court also denied TRO/PI against FDA.","R&D expense fell 47% to $9.4M (no prior-year license fee); G&A rose 116% to $20.0M on sales force and legal costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086529","json":"https://secwatch.observer/filing/0001104659-24-086529.json","markdown":"https://secwatch.observer/filing/0001104659-24-086529.md","text":"https://secwatch.observer/filing/0001104659-24-086529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924086529/0001104659-24-086529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924086529/tm2420885d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:52:08.636438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}